

.....  
(Original Signature of Member)

118TH CONGRESS  
2D SESSION

**H. R.** \_\_\_\_\_

To amend the Office of National Drug Control Policy Reauthorization Act  
to reauthorize such Office, and for other purposes.

\_\_\_\_\_  
**IN THE HOUSE OF REPRESENTATIVES**

Mr. COMER introduced the following bill; which was referred to the Committee  
on \_\_\_\_\_

\_\_\_\_\_  
**A BILL**

To amend the Office of National Drug Control Policy Reau-  
thorization Act to reauthorize such Office, and for other  
purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Office of National  
5 Drug Control Policy Reauthorization Act of 2024”.

1 **SEC. 2. OFFICE OF NATIONAL DRUG CONTROL POLICY RE-**  
2 **AUTHORIZATION.**

3 (a) AMENDMENTS TO THE OFFICE OF NATIONAL  
4 DRUG CONTROL POLICY ACT OF 1998.—The Office of  
5 National Drug Control Policy Reauthorization Act of 1998  
6 (21 U.S.C. 1701 et seq.) is amended—

7 (1) in section 702 (21 U.S.C. 1701)—

8 (A) in paragraph (2)(A)(ii), by striking  
9 “Government Reform” and inserting “Account-  
10 ability”;

11 (B) in paragraph (3)—

12 (i) in subparagraph (L), by striking “;  
13 and” and inserting a semicolon;

14 (ii) in subparagraph (M), by striking  
15 the period at the end and inserting “;  
16 and”; and

17 (iii) by adding at the end the fol-  
18 lowing:

19 “(N) tertiary prevention support or serv-  
20 ices, including opioid antagonists or overdose  
21 reversal agents such as naloxone, and other  
22 harm reduction activities such as overdose and  
23 drug detection testing.”;

24 (C) by amending paragraph (7) to read as  
25 follows;;

1           “(7) EMERGING DRUG THREAT.—The term  
2           ‘emerging drug threat’ means the occurrence of a  
3           new and growing trend in the illicit use or misuse  
4           of a drug, class of drugs, or non-controlled sub-  
5           stance, or a new or evolving method of drug con-  
6           sumption or trafficking, including rapid expansion in  
7           the supply of or demand for such a drug or sub-  
8           stance.”.

9           (D) in paragraph (9), by striking “drug  
10           laws” and inserting the following: “drug, trade,  
11           and illicit drug trafficking laws”;

12           (E) in paragraph (10), by inserting after  
13           “demand reduction,” the following: “illicit drug  
14           trafficking,”;

15           (F) by redesignating paragraphs (15),  
16           (16), and (17) as paragraphs (17), (18), and  
17           (19), respectively;

18           (G) by inserting after paragraph (14) the  
19           following new paragraph:

20           “(15) PRECURSOR CHEMICAL.—

21           “(A) IN GENERAL.—The term ‘precursor  
22           chemical’ includes a listed chemical and an un-  
23           regulated precursor.

24           “(B) LISTED CHEMICAL.—The term ‘listed  
25           chemical’ has the meaning given that term in

1 section 102 of the Controlled Substances Act  
2 (21 U.S.C. 802).

3 “(C) UNREGULATED PRECURSOR.—The  
4 term ‘unregulated precursor’—

5 “(i) means any chemical used in the  
6 production of illicit drugs that has not  
7 been identified as a listed chemical under  
8 the Controlled Substances Act; and

9 “(ii) does not include a solvent or rea-  
10 gent.

11 “(16) STATE.—The term ‘State’ means each of  
12 the several States of the United States, the District  
13 of Columbia, and each territory or possession of the  
14 United States.”;

15 (H) in paragraph (19), as so redesign-  
16 nated—

17 (i) by redesignating subparagraphs  
18 (G) and (H) as subparagraphs (H) and  
19 (I), respectively; and

20 (ii) by inserting after subparagraph  
21 (F) the following:

22 “(G) activities to map, track, dismantle,  
23 and disrupt the financial enablers of drug traf-  
24 ficking organizations, transnational criminal or-  
25 ganizations, and money launderers involved in

1 the manufacture and trafficking of drugs in the  
2 United States and in foreign countries;” and

3 (I) by inserting at the end the following:

4 “(20) UNITED STATES.—The term ‘United  
5 States’, when used in a geographical sense, means  
6 all of the States, the District of Columbia, and the  
7 territories and possessions of the United States, and  
8 any waters within the jurisdiction of the United  
9 States.

10 “(21) EVIDENCE.—The term ‘evidence’ has the  
11 meaning given that term in section 3561 of title 44,  
12 United States Code.”;”;

13 (2) in section 703(d) (21 U.S.C. 1702(d))—

14 (A) in paragraph (5)(B), by striking “ac-  
15 cepted by a contractor to be used in its per-  
16 formance of a contract for the Office” and in-  
17 serting the following: “accepted—

18 “(i) by a contractor (or subcontractor  
19 thereof at any tier) for use in its perform-  
20 ance of a contract for the Office; or

21 “(ii) by a grant recipient (or sub-  
22 grantee thereof at any tier) for use in car-  
23 rying out an award related to a fund ad-  
24 ministered by the Office.”; and

1 (B) in paragraph (6), by inserting after  
2 “paragraph (5)” the following: “and the reg-  
3 istry shall be sent to the appropriate Congres-  
4 sional committees”;

5 (3) in section 704 (21 U.S.C. 1703)—

6 (A) in subsection (a)(1)(C), by striking  
7 “shall” and inserting “may”;

8 (B) in subsection (b)—

9 (i) in paragraph (16), by inserting  
10 after “to treat addiction” the following: “,  
11 encourage primary substance use preven-  
12 tion, and increase accessibility and effec-  
13 tiveness of life-saving opioid antagonists or  
14 reversal agents, such as naloxone”;

15 (ii) by striking paragraph (20);

16 (iii) by redesignating paragraph (21)  
17 as paragraph (20);

18 (iv) in paragraph (20), as so redesign-  
19 ated, by striking the period at the end  
20 and inserting “; and”; and

21 (v) by inserting at the end the fol-  
22 lowing:

23 “(21) shall coordinate with the Secretary of  
24 Homeland Security, the Attorney General, and the  
25 Secretary of State to regarding the status of the en-

1 enforcement of clauses (i) and (ii) of subparagraph (A)  
2 and subparagraph (B) of section 237(a)(2) (8  
3 U.S.C. 1227(a)(2)) and subparagraphs (A) and (C)  
4 of section 212(a)(2) (8 U.S.C. 1182(a)(2) for the  
5 purposes of ensuring such drug control and illicit  
6 drug trafficking enforcement activities are ade-  
7 quately resourced.”;

8 (C) in subsection (c)—

9 (i) in paragraph (1)(C), by striking  
10 “supply reduction, and State, local, and  
11 tribal affairs, including any drug law en-  
12 forcement activities” and inserting the fol-  
13 lowing: “supply reduction, accessibility to  
14 life-saving opioid antagonists or reversal  
15 agents, such as naloxone, and State, local,  
16 and Tribal affairs, including any drug re-  
17 lated law enforcement activities”;

18 (ii) in paragraph (3)(C)—

19 (I) in clause (ii), by inserting  
20 after “United States” the following: “,  
21 including at and between the ports of  
22 entry,”;

23 (II) in clause (iii), by striking “;  
24 and” and inserting a semicolon;

1 (III) in clause (iv), by striking  
2 the period at the end and inserting “;  
3 and”; and

4 (IV) by inserting at the end the  
5 following new clause:

6 “(v) requests funding for activities  
7 that facilitate illicit drug use, but not in-  
8 cluding overdose reversal medications, drug  
9 checking, or testing technology.”;

10 (D) in subsection (d)(8)(F)(ii), by striking  
11 “and at United States ports of entry by officers  
12 and employees of National Drug Control Pro-  
13 gram agencies and domestic and foreign law en-  
14 forcement officers” and inserting the following:  
15 “and at and between United States ports of  
16 entry by officers and employees of National  
17 Drug Control Program agencies and domestic  
18 and foreign law enforcement officers”;

19 (E) in subsection (i)—

20 (i) in paragraph (1)(A), by striking  
21 “to address illicit drug use issues” and in-  
22 serting the following: “to address illicit  
23 drug use, prevention and treatment of  
24 overdose and addiction, and law enforce-  
25 ment activities”; and



1 (ii) in paragraph (2), by striking  
2 “2023” and inserting “2031”; and  
3 (F) in subsection (k)—

4 (i) in the heading, by striking “HARM  
5 REDUCTION PROGRAMS” and inserting  
6 “SUBSTANCE USE PREVENTION, HARM  
7 REDUCTION, AND LIFE-SAVING TREAT-  
8 MENT PROGRAMS”; and

9 (ii) in the first sentence, by inserting  
10 after “drug addiction and use” the fol-  
11 lowing: “with the primary goal being the  
12 prevention of initial or continued use and  
13 the fostering of life-saving opioid antago-  
14 nists or reversal agents, such as naloxone”;

15 (4) in section 705 (21 U.S.C. 1704)—

16 (A) in subsection (a)(3)—

17 (i) in subparagraph (A), by inserting  
18 after “Federal Government” the following:  
19 “and such lands owned by a foreign prin-  
20 cipal (as such term in defined in section  
21 1(b) of the Foreign Agents Registration  
22 Act of 1938 (22 U.S.C. 611)”;

23 (ii) in subparagraph (B)—

24 (I) by inserting after “the pre-  
25 ceding year” the following: “, along

1 with historical comparisons over the  
2 prior 20 years,”;

3 (II) in clause (i)—

4 (aa) by inserting after “seiz-  
5 ing drugs,” the following: “in-  
6 cluding precursor chemicals,”;  
7 and

8 (bb) by striking “; and” and  
9 inserting a semicolon;

10 (III) in clause (ii), by striking  
11 the period at the end and inserting “;  
12 and’ ” and

13 (IV) by inserting at the end the  
14 following new clause:

15 “(iii) the effects of trends of encoun-  
16 ters of inadmissible aliens at and between  
17 the ports of entry, and the effect of any in-  
18 creases or changes in the level of trade and  
19 travel, on the capacity and ability of the  
20 Department of Homeland Security compo-  
21 nents to interdict and prevent the unlawful  
22 entry of illicit drugs into the United States  
23 by any means.”; and

24 (iii) in subparagraph (D)—

1 (I) by inserting after “the pre-  
2 ceding year” the following: “, along  
3 with historical comparisons over the  
4 prior 20 years,”; and

5 (II) in clause (iii), by inserting  
6 after “seizing drugs,” the following:  
7 “including precursor chemicals,”;

8 (B) in subsection (e)(2), by inserting be-  
9 fore the period at the end the following: “and  
10 \$3,000,000 for each of fiscal years 2025  
11 through 2031”; and

12 (C) in subsection (f)—

13 (i) in paragraph (2), by inserting after  
14 “agency shall” the following: “, in accord-  
15 ance with guidelines issued by the Director  
16 for standard definitions, identification, and  
17 review procedures,”; and

18 (ii) by striking paragraph (4);

19 (5) in section 706 (21 U.S.C. 1705)—

20 (A) in subsection (c)—

21 (i) in paragraph (1)—

22 (I) by striking subparagraph (D);

23 (II) in subparagraph (H)—

1 (aa) by inserting after  
2 “identifying existing” the fol-  
3 lowing: “evidence,”; and

4 (bb) by striking “will obtain  
5 such data” and inserting “will  
6 ensure such data is obtained”;

7 (III) in subparagraph (J)(ii), by  
8 inserting “evidence,” before “data”;

9 (IV) in subparagraph (L), by in-  
10 sserting “evidence” after “Such other”;  
11 and

12 (V) in subparagraph (M)(iv), by  
13 inserting “storing and retrieving,”  
14 after “collecting,”;

15 (ii) in paragraph (2)—

16 (I) by redesignating subpara-  
17 graphs (E) and (F) as subparagraphs  
18 (G) and (H), respectively; and

19 (II) by inserting after subpara-  
20 graph (D) the following new subpara-  
21 graphs:

22 “(E) The Administrator of the Office of  
23 Information and Regulatory Affairs.

24 “(F) The Chief Data Officers Council.”;

25 (iii) in paragraph (3)—

1 (I) in subparagraph (B)(ii)—

2 (aa) in subclause (I), by  
3 striking “; and”;

4 (bb) in subclause (II), by  
5 striking the period at the end  
6 and inserting “; and”; and

7 (cc) by inserting at the end  
8 the following new subclause:

9 “(III) an analysis of the effects  
10 of trends of encounters of inadmis-  
11 sible aliens at and between the ports  
12 of entry, and the effect of any in-  
13 creases or changes in the level of  
14 trade and travel, on the capacity and  
15 ability of the Department of Home-  
16 land Security to interdict and prevent  
17 the unlawful entry of illicit drugs into  
18 the United States by any means.”;  
19 and

20 (II) by adding at the end the fol-  
21 lowing new subparagraph:

22 “(D) REQUIREMENT FOR CARIBBEAN BOR-  
23 DER COUNTERNARCOTICS STRATEGY.—

24 “(i) PURPOSES.—The Caribbean Bor-  
25 der Counternarcotics Strategy shall—

1 “(I) set forth the strategy of the  
2 Federal Government for preventing  
3 the illegal trafficking of drugs through  
4 the Caribbean region into the United  
5 States, including through ports of  
6 entry, between ports of entry, and  
7 across air and maritime approaches;

8 “(II) state the specific roles and  
9 responsibilities of each relevant Na-  
10 tional Drug Control Program agency  
11 for implementing the strategy;

12 “(III) identify the specific re-  
13 sources required to enable the relevant  
14 National Drug Control Program agen-  
15 cies to implement the strategy, to the  
16 extent practicable; and

17 “(IV) be designed to promote,  
18 and not hinder, legitimate trade and  
19 travel.

20 “(ii) SPECIFIC CONTENT RELATED TO  
21 PUERTO RICO AND THE UNITED STATES  
22 VIRGIN ISLANDS.—The Caribbean Border  
23 Counternarcotics Strategy shall include—

24 “(I) a strategy to prevent the il-  
25 legal trafficking of drugs to or

1 through Puerto Rico and the United  
2 States Virgin Islands, including meas-  
3 ures to substantially reduce drug-re-  
4 lated violent crime on such islands;  
5 and

6 “(II) recommendations for addi-  
7 tional assistance or authorities, if any,  
8 needed by Federal, State, and local  
9 law enforcement agencies relating to  
10 the strategy, including an evaluation  
11 of Federal technical and financial as-  
12 sistance, infrastructure capacity build-  
13 ing, and interoperability deficiencies.”;  
14 and

15 (iv) in paragraph (5), by striking  
16 “data” each place it appears and inserting  
17 “evidence, data,”;  
18 (B) in subsection (f)—

19 (i) in paragraph (1), by striking “pub-  
20 licly available in a machine-readable for-  
21 mat” and inserting the following: “publicly  
22 available as an open Government data  
23 asset (as such term is defined in section  
24 3502 of title 44, United States Code)”;

1 (ii) in paragraph (2), by inserting  
2 after “searchable format” the following:  
3 “available for bulk download to the extent  
4 practicable”; and

5 (iii) by amending paragraph (3) to  
6 read as follows:

7 “(3) DATA.—The data included in the Drug  
8 Control Data Dashboard shall be updated annually  
9 with final data, and to the extent practicable, up-  
10 dated quarterly with provisional data, that aligns  
11 with the goals of the performance measurement sys-  
12 tem required under subsection (h) and include, at a  
13 minimum, the following:

14 “(A) For each substance identified by the  
15 Director as having a significant impact on illicit  
16 drug use in the United States, data sufficient  
17 to—

18 “(i) assess supply reduction efforts,  
19 including, to the extent practicable, the  
20 total amount of substances seized;

21 “(ii) assess drug use behaviors;

22 “(iii) estimate the prevalence of sub-  
23 stance use disorders;

24 “(iv) show the number of fatal and  
25 non-fatal overdoses; and



1                   “(v) assess the provision of substance  
2                   use disorder treatment.

3                   “(B) Any quantifiable measures the Direc-  
4                   tor determines to be appropriate to detail  
5                   progress toward the achievement of the goals of  
6                   the National Drug Control Strategy, including,  
7                   to the extent practicable, data disaggregated by  
8                   specific geographic areas or sub-populations of  
9                   interest.

10                  “(C) Data sufficient to assess the effective-  
11                  ness of such substance use disorder treatments.

12                  “(D) To the extent practicable, data suffi-  
13                  cient to show the extent of prescription drug di-  
14                  version, trafficking, and misuse in the calendar  
15                  year and each of the previous 3 calendar years.

16                  “(E) Any quantifiable measures the Direc-  
17                  tor determines to be appropriate to detail  
18                  progress toward the achievement of the goals of  
19                  the National Drug Control Strategy, including  
20                  to the extent practicable, data disaggregated by  
21                  specific geographic areas or sub-populations of  
22                  interest.”; and

23                  (C) in subsection (g)(2)—

24                         (i) in subparagraph (D), by striking  
25                         “narcotics” and inserting “drugs”;

1 (ii) in subparagraph (E), by striking  
2 “drug use” and inserting “illegal drug  
3 use”; and

4 (iii) in subparagraph (F), by striking  
5 “drug use” and inserting “illegal drug  
6 use”;

7 (6) in section 707 (21 U.S.C. 1706)—

8 (A) in subsection (l)(2)(F), by inserting  
9 “and authorities enforcing illicit drug traf-  
10 ficking laws” after “task forces”;

11 (B) in subsection (m)(2), by inserting “,  
12 authorities enforcing illicit drug trafficking  
13 laws,” after “agencies”;

14 (C) in subsection (p)—

15 (i) in paragraph (5), by striking “;  
16 and” and inserting a semicolon;

17 (ii) in paragraph (6), by striking the  
18 period at the end and inserting “; and”;  
19 and

20 (iii) by inserting at the end the fol-  
21 lowing new paragraph:

22 “(7) \$298,579,000 for each of fiscal years 2025  
23 through 2031.”;

24 (D) in subsection (s)—

1 (i) in the matter before paragraph  
2 (1), by striking “The Director” and insert-  
3 ing “Except as provided in subsection  
4 (t)(2), the Director”;

5 (ii) in paragraph (2), by striking “;  
6 and” and inserting a semicolon;

7 (iii) in paragraph (3), by striking the  
8 period at the end and inserting “; and”;  
9 and

10 (iv) by adding at the end the fol-  
11 lowing:

12 “(4) enhancing fentanyl seizure and interdiction  
13 activities.”; and

14 (E) by adding at the end the following:

15 “(t) SUPPLEMENTAL GRANTS FOR FENTANYL  
16 INTERDICTION ACTIVITIES.—

17 “(1) MINIMUM ALLOCATION OF FUNDS FOR  
18 FENTANYL INTERDICTION ACTIVITIES.—Of the  
19 amounts allocated for grants under subsection (s),  
20 not less than \$5,000,000 shall be allocated for the  
21 purpose of making grants under subsection (s)(4).

22 “(2) ADDITIONAL FUNDS.—In addition to  
23 amounts allocated under subparagraph (A) for the  
24 purpose of making grants under subsection (s)(4),

1 the Director may use amounts otherwise appro-  
2 priated to carry out this section for such purpose.

3 “(u) ADDITIONAL JUDICIARY PROSECUTORIAL RE-  
4 SOURCES.—

5 “(1) TEMPORARY REASSIGNMENT OF ASSIST-  
6 ANT UNITED STATES ATTORNEYS.—

7 “(A) AUTHORITY.—The Attorney General  
8 may identify assistant United States attorneys  
9 who may be made available for temporary reas-  
10 signment under subsection (b)(2) for a period  
11 of time determined by the Attorney General in  
12 coordination with the Director, during which an  
13 assistant United States attorney shall prioritize  
14 the investigation and prosecution of organiza-  
15 tions and individuals trafficking in fentanyl or  
16 fentanyl analogues.

17 “(B) EXTENSION OF REASSIGNMENT.—  
18 Such reassignment may be extended by the At-  
19 torney General for such time as may be nec-  
20 essary to conclude any ongoing investigation or  
21 prosecution in which the assistant United  
22 States attorney is engaged.

23 “(2) PROCESS FOR TEMPORARY REASSIGN-  
24 MENT.—The Attorney General may establish a proc-  
25 ess under which the Director, in consultation with

1 the Executive Boards of each designated high inten-  
2 sity drug trafficking area, may request such an as-  
3 sistant United States attorney to be so temporarily  
4 reassigned.

5 “(v) USE OF FUNDS TO COMBAT FENTANYL TRAF-  
6 FICKING.—

7 “(1) REQUIREMENT.—As part of the docu-  
8 mentation that supports the President’s annual  
9 budget request for the Office, the Director shall sub-  
10 mit to Congress a report describing the use of  
11 HIDTA funds for the purposes of enhancing  
12 fentanyl seizure and interdiction activities under  
13 subsection (s)(4) or (t) and to investigate and pros-  
14 ecute organizations and individuals trafficking in  
15 fentanyl or fentanyl analogues in the prior calendar  
16 year.

17 “(2) CONTENTS.—The report shall include—

18 “(A) the amounts of fentanyl or fentanyl  
19 analogues seized by HIDTA-funded initiative in  
20 the area during the previous year; and

21 “(B) law enforcement intelligence and pre-  
22 dictive data from the Drug Enforcement Ad-  
23 ministration showing patterns and trends in  
24 abuse, trafficking, and transportation in  
25 fentanyl and fentanyl analogues.

1           “(w) REPORT ON DATA ANALYTICAL SERVICES PRO-  
2 GRAM.—

3           “(1) REPORT.—With respect to the Data Ana-  
4 lytical Services program (formally known as Hemi-  
5 sphere), and any successor program, the Director  
6 shall submit to the Committee on Oversight and Ac-  
7 countability and the Committee on the Judiciary of  
8 the House of Representatives, and the Committee on  
9 the Judiciary of the Senate a report every two years  
10 on any activities of the program—

11                   “(A) funded by the Office; and

12                   “(B) carried out in two years prior to the  
13 submission of the report.

14           “(2) CONTENTS OF REPORT.—The report re-  
15 quired by paragraph (1) shall include the following:

16                   “(A) A documentation of any activities of  
17 the Data Analytical Services program, includ-  
18 ing—

19                           “(i) the amount of searches conducted  
20 for each HIDTA; and

21                           “(ii) each requesting local law enforce-  
22 ment jurisdiction.

23                   “(B) Information on how the program was  
24 funded and how funds were expended under the  
25 program, including information on any—

1           “(i) funding sources derived from  
2           each HIDTA’s funding allocation for a  
3           HIDTA, or any other source of funding,  
4           for the program; and

5           “(ii) payments made by the program  
6           to any non-governmental entity or external  
7           vendor.

8           “(C) A description of any policies and  
9           guidelines provided to HIDTA personnel and  
10          local law enforcement jurisdictions governing  
11          the operation of the program in order to ensure  
12          that such program does not infringe on rights  
13          protected under the Fourth Amendment or vio-  
14          late legally protected privacy of United States  
15          citizens or individuals legally in the United  
16          States, along with any recommendations by the  
17          Director to strengthen such policies and guide-  
18          lines.”;

19          (7) in section 709(f)(1) (21 U.S.C. 1708(f)(1)),  
20          by striking “shall” and inserting “may”;

21          (8) in section 709 (21 U.S.C. 1708)—

22                 (A) in subsection (f)(2)(B)(iii), by insert-  
23                 ing after “professionals” the following: “includ-  
24                 ing experts in evidence-based media campaigns,  
25                 education, and evaluation”; and

1 (B) in subsection (g), by striking “2023”  
2 and inserting “2031”;

3 (9) in section 711 (21 U.S.C. 1710), including  
4 the headings, by striking “Command and Control  
5 Plan” each place it appears and inserting “Strategic  
6 Plan”; and

7 (10) in section 714 (21 U.S.C. 1711), by insert-  
8 ing before the period at the end the following: “and  
9 \$20,000,000 for each of fiscal years 2025 through  
10 2031”.

11 (b) AMENDMENTS TO THE ANTI-DRUG ABUSE ACT  
12 OF 1988.—The Anti-Drug Abuse Act of 1988 (Public Law  
13 100–690) is amended—

14 (1) in section 1024(a) (21 U.S.C. 1524(a)), by  
15 inserting before the period at the end the following:  
16 “and \$109,000,000 for each of fiscal years 2025  
17 through 2031”; and

18 (2) in section 1032(b) (21 U.S.C. 1532(b))—

19 (A) by striking “\$125,000” each place the  
20 term appears and inserting “\$150,000”; and

21 (B) in paragraph (3)—

22 (i) by striking subparagraph (A) and  
23 inserting the following:

24 “(A) IN GENERAL.—Subject to subpara-  
25 graph (F), the Administrator may award up to



1           2 additional grants under this paragraph to an  
2           eligible coalition awarded a grant under para-  
3           graph (1) or (2) for any first fiscal year after  
4           the end of the 4-year or 9-year period following  
5           the period of the initial or subsequent grant  
6           under paragraph (1) or (2), as the case may  
7           be.”;

8                   (ii) in subparagraph (B), by striking  
9                   “a renewal grant” and inserting “up to 2  
10                  renewal grants”;

11                   (iii) in subparagraph (C), by striking  
12                   “an additional grant” and inserting “the  
13                  additional grants”; and

14                   (iv) by striking subparagraph (D) and  
15                  inserting the following:

16                  “(D) RENEWAL GRANTS.—Subject to sub-  
17                  paragraph (F), the Administrator may award a  
18                  renewal grant to a grant recipient under this  
19                  paragraph for each fiscal year of the 4-fiscal-  
20                  year period following the first fiscal year for  
21                  which an additional grant under this paragraph  
22                  is awarded in an amount not to exceed the  
23                  amount of non-Federal funds raised by the coa-  
24                  lition, including in-kind contributions, for that  
25                  fiscal year.”.

1           (c) REAUTHORIZATION OF THE NATIONAL COMMU-  
2 NITY ANTI-DRUG COALITION INSTITUTE.—Section 4(d)  
3 of Public Law 107-82 (21 U.S.C. 1521 note) is amended  
4 by striking “section 1032 of the National Narcotics Lead-  
5 ership Act of 1988 (15 U.S.C. 1532), make a grant of  
6 \$2 million under subsection (a), for each of the fiscal years  
7 2018 through 2023” and inserting “section 1024 of the  
8 National Narcotics Leadership Act of 1988 (21 U.S.C.  
9 1524), make a grant of \$2,500,000 under subsection (a),  
10 for each of the fiscal years 2025 through 2031”.

11           (d) REAUTHORIZATION OF COMMUNITY-BASED COA-  
12 LITION ENHANCEMENT GRANTS TO ADDRESS LOCAL  
13 DRUG CRISES.—Subsection (i) of section 103 of the Com-  
14 prehensive Addiction and Recovery Act of 2016 (21 U.S.C.  
15 1536) is amended by inserting before the period at the  
16 end the following: “and \$5,200,000 for each of fiscal years  
17 2025 through 2031”.

18           (e) REPORT REGARDING LIFE-SAVING OPIOID AN-  
19 TAGONISTS OR REVERSAL AGENTS.—The Office of Na-  
20 tional Drug Control Policy Reauthorization Act of 2006  
21 (Public Law 109–469) is amended by adding at the end  
22 the following new section:

1 **“SEC. 1121. REQUIREMENT FOR LIFE SAVING OPIOID OVER-**  
2 **DOSE REVERSAL STUDY.**

3 “(a) FINDING.—Congress finds that it is vital to sup-  
4 port access to treatment and emergency intervention tools  
5 to address drug addiction while also pursuing strategies  
6 to ensure communities have readily available access to life-  
7 saving drug overdose reversal medications, including  
8 opioid antagonists or reversal agents, such as naloxone,  
9 in case of an emergency.

10 “(b) REPORT.—Not later than 180 days after the  
11 date of the enactment of this section, the Director of the  
12 Office of National Drug Control Policy shall submit to  
13 Congress a report that contains the following:

14 “(1) A summary of the relevant roles, respon-  
15 sibilities, and authorities of each relevant National  
16 Drug Control Program agency to ensure that life-  
17 saving drug overdose reversal medications are read-  
18 ily available in case of an emergency, including life-  
19 saving opioid antagonists or reversal agents, such as  
20 naloxone, across the Nation.

21 “(2) A strategy for the Federal Government to  
22 ensure that State, local, and Tribal governments,  
23 and agencies thereof including law enforcement and  
24 public health and safety entities, have life-saving  
25 drug overdose reversal medications readily available  
26 in case of an emergency, including life-saving opioid

1           antagonists or reversal agents, such as naloxone,  
2           which at a minimum identifies—

3                   “(A) any Federal and State policies and  
4                   actions necessary for the relevant National  
5                   Drug Control Program agencies to take to ad-  
6                   dress—

7                           “(i) the challenges faced by phar-  
8                           macists, prescription drug providers, dis-  
9                           pensers (including manufacturers, distribu-  
10                           tors, and retailers), and other health care  
11                           providers, to make such medications read-  
12                           ily available to patients over the counter  
13                           for emergency use;

14                           “(ii) the challenges faced by phar-  
15                           macists, health care providers, and State  
16                           health officials to educate the public on the  
17                           risks and benefits of such medications, in-  
18                           cluding how to effectively use such medica-  
19                           tions; and

20                           “(iii) the appropriate training of State  
21                           and local health care providers and first  
22                           responders on the use of such medications;  
23                           and

24                           “(B) identifies any budgetary resources,  
25                           personnel resources, licensing requirements, and

1 legal authorities that relevant National Drug  
2 Control Program agencies needs to enable the  
3 availability of such life-saving emergency drug  
4 overdose medications;

5 “(3) A summary of policies in effect before the  
6 submission of the report that are administered by—

7 “(A) the Director of the Office National  
8 Drug Control Policy;

9 “(B) the Secretary of Health and Human  
10 Services; and

11 “(C) each National Drug Control Program  
12 agency, as applicable.

13 “(4) A summary of the specific actions taken  
14 over the previous 10 years before the submission of  
15 the report by the Substance Abuse and Mental  
16 Health Services Administration and the Drug En-  
17 forcement Administration to coordinate with one an-  
18 other and with State health agencies to ensure  
19 that—

20 “(A) such treatments, including medica-  
21 tions, are accessible to the public; and

22 “(B) appropriate public education on the  
23 use of, and the risks and benefits of, such treat-  
24 ments, including medications, are readily avail-  
25 able.

1           “(c) UPDATES.—Any significant update made to the  
2 strategy included in the report required by paragraph  
3 (2)(B) after such report is submitted shall be included in  
4 the next National Drug Control Strategy submitted to  
5 Congress after such update is made.”.